As shown in Figure 4B, doses of tetracenomycin X at 2.5 and 5 μmol/L abated the levels of cyclin D1 and CDK4 (cyclin-dependent kinase 4) in the five lung cancer cells. Here, CCND1 is linked to lung cancer.